Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
0.5601
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
32
33
Next >
Lexaria (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Tech on EDGE Podcast
February 01, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Offers a Glimpse into Company’s Unique Technology and Operations on EDGE Podcast
January 31, 2022
Via
Investor Brand Network
Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
↗
January 28, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Lexaria (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
January 28, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emphasizes Oral Cannabinoid Delivery Benefits Following SARS-CoV-2 Study
January 27, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
January 27, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update
January 27, 2022
Via
Investor Brand Network
Lexaria Provides Annual Letter From the CEO
January 27, 2022
KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs
↗
January 21, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs
January 21, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval
January 20, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
January 20, 2022
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
January 20, 2022
Via
CannabisNewsWire
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2
↗
January 19, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Comments on Study Examining Cannabinoids and SARS-CoV-2
January 19, 2022
Via
Investor Brand Network
Topics
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Via
Investor Brand Network
Topics
Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Via
CannabisNewsWire
Topics
Cannabis
Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine
↗
January 18, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Leveraging DehydraTECH(TM) for More Effective Oral Medicine
January 18, 2022
Via
Investor Brand Network
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"...
From
Lexaria Bioscience Corp.
Via
AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
January 14, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
January 14, 2022
Via
Investor Brand Network
After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements
January 14, 2022
Via
Investor Brand Network
Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution
↗
January 12, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience’s ongoing...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution
January 12, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022
January 12, 2022
Via
Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
↗
January 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received approval from the...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
January 11, 2022
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Independent Review Board Approval for Its Most Ambitious, Comprehensive Human Study Yet
January 10, 2022
Via
Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
↗
January 07, 2022
Gainers ContraFect (NASDAQ:CFRX) stock mo...
Via
Benzinga
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
